ELI LILLY to soon start a correction towards $700.Eli Lilly (LLY) has made new All Time Highs (ATH) this month, extending the impressive rally since the August Low near the 1W MA200 (orange trend-line).
The multi-year trend remains bullish within a Fibonacci Channel Up but practically the stock hasn't gotten out of its range since the July 2024 Hi
Key facts today
Eli Lilly plans a $5 billion investment in a Virginia manufacturing facility, part of a $27 billion expansion of its U.S. operations over the next five years.
JP Morgan has raised its price target for Eli Lilly (LLY) shares to $1150.00 from a previous target of $1050.00.
Eli Lilly aims for a trillion-dollar market value, driven by its obesity drug Zepbound, which has gained substantial market share against rivals like Novo Nordisk's Wegovy.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
20.25 USD
10.59 B USD
45.04 B USD
850.14 M
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
US5324571083
FIGI
BBG01LGV45L7
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Eli Lilly Testing $1000 — Breakout or Fakeout?After consolidating for over a year inside a descending channel, LLY has rallied back to the top resistance zone around $1000.
Bullish Case:
• Breakout above $1000 = start of new uptrend.
• Targets: $1100 → $1200.
Bearish Case:
• Rejection at $1000 could pull price back to $850–$800, or eve
Eli Lilly Drug Shows New Potential in Curbing Food CravingsEli Lilly’s GLP-1 weight-loss drug tirzepatide — sold as Mounjaro and Zepbound — may do more than suppress appetite. A new Nature Medicine report shows that in one patient with severe binge-eating behavior, the drug appeared to silence food-craving signals in the brain’s reward center. This is the f
LLY - Massive Bullflag in a Multi-year uptrendLLY will absolutely outperform in the next couple of months.
Pair a technically flawless chart with a huge bullflag breakout with positive headwind "Google: Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage" and coming QE and you have
"LLY's Bear Market Mode ON | Crash Incoming"“ LLY is gearing up for a sharp correction down to the $35–$17 zone — a critical reset that could flush out weak hands before the next explosive bull run. Stay sharp, this is where big opportunities form. ⚠️
🔥 Summary:
Eli Lilly (LLY) looks ready for a major market reset after completing a
$LLY: Decision Zone — Wedge Breakout or Retest of 685Eli Lilly (LLY) rebounded off the long-term trendline and weekly demand box (≈622–686) and is compressing inside a descending wedge.
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the
Eli Lilly and Company: Path to Sustained Market LeadershipEli Lilly and Company has achieved a market valuation approaching one trillion U.S. dollars by the close of 2025, underpinned by a comprehensive corporate strategy that integrates advanced scientific research, targeted technology acquisitions, and adaptive global partnerships. This performance, mark
$LLYThe technical structure for NYSE:SMR presents a compelling case of a strong, sustained uptrend, characterized by a rhythmic pattern of sharp advances followed by periods of consolidation. This behavior is the hallmark of a healthy, momentum-driven bull move.
1. Pattern Analysis: Sequential Bull F
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043Yield to maturity
5.73%
Maturity date
Sep 14, 2043
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
5.65%
Maturity date
Jun 15, 2044
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065Yield to maturity
5.56%
Maturity date
Oct 15, 2065
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059Yield to maturity
5.54%
Maturity date
Mar 15, 2059
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064Yield to maturity
5.53%
Maturity date
Feb 9, 2064
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064Yield to maturity
5.52%
Maturity date
Aug 14, 2064
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065Yield to maturity
5.51%
Maturity date
Feb 12, 2065
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
5.51%
Maturity date
Feb 27, 2063
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053Yield to maturity
5.46%
Maturity date
Feb 27, 2053
US532457BT4
Eli Lilly and Company 3.95% 15-MAR-2049Yield to maturity
5.45%
Maturity date
Mar 15, 2049
LLY6153502
Eli Lilly and Company 5.55% 15-OCT-2055Yield to maturity
5.45%
Maturity date
Oct 15, 2055
See all LLY bonds
Curated watchlists where LLY is featured.
Frequently Asked Questions
The current price of LLY is 1,024.00 USD — it has decreased by −0.05% in the past 24 hours. Watch Eli Lilly and Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BVL exchange Eli Lilly and Company stocks are traded under the ticker LLY.
LLY stock has risen by 7.79% compared to the previous week, the month change is a 28.81% rise, over the last year Eli Lilly and Company has showed a 26.65% increase.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLY price has a max estimate of 1,500.00 USD and a min estimate of 775.00 USD. Watch LLY chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLY stock is 0.05% volatile and has beta coefficient of 0.48. Track Eli Lilly and Company stock price on the chart and check out the list of the most volatile stocks — is Eli Lilly and Company there?
Today Eli Lilly and Company has the market capitalization of 965.90 B, it has increased by 10.66% over the last week.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Feb 11, 2026. Keep track of upcoming events with our Earnings Calendar.
LLY earnings for the last quarter are 7.02 USD per share, whereas the estimation was 5.69 USD resulting in a 23.33% surprise. The estimated earnings for the next quarter are 7.08 USD per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to 17.60 B USD, despite the estimated figure of 16.05 B USD. In the next quarter, revenue is expected to reach 17.57 B USD.
LLY net income for the last quarter is 5.58 B USD, while the quarter before that showed 5.66 B USD of net income which accounts for −1.38% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLY dividends are paid quarterly. The last dividend per share was 1.50 USD. As of today, Dividend Yield (TTM)% is 0.57%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.67% in 2024, and payout ratio reached 44.39%. The year before the numbers were 0.78% and 77.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 19, 2025, the company has 47 K employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is 28.29 B USD, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eli Lilly and Company technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eli Lilly and Company stock shows the strong buy signal. See more of Eli Lilly and Company technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.













